PeptideDB

Fluoroethylnormemantine

CAS: 1639210-26-6 F: C12H20FN W: 197.29

Fluoroethylnormemantine, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. -Fluor
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Fluoroethylnormemantine, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [18F]-Fluoroethylnormemantine can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects[1][2][3].
Target NMDA receptor
In Vivo Fluoroethylnormemantine (0.1-10 mg/kg; a single i.p.) shows anti-amnesic effects on Aβ 25-35-induced learning impairments in mice[1].Fluoroethylnormemantine (0.1-10 mg/kg; i.p. once daily for 7 days) attenuates Aβ 25-35-induced behavioral deficits, neuroinflammation, oxidative stress, apoptosis, and cell loss in mice[1].Fluoroethylnormemantine (1-20 mg/kg; a single injection) decreases behavioral despair in the forced swim test (FST) and reduces fear behavior in the cued fear conditioning (FC) and extinction training in rats[2]. Animal Model:
Name Fluoroethylnormemantine
CAS 1639210-26-6
Formula C12H20FN
Molar Mass 197.29
Transport Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Reference [1]. Couly S, et, al. Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer's Disease. Int J Neuropsychopharmacol. 2021 Feb 15;24(2):142-157. [2]. Chen BK, et, al. Fluoroethylnormemantine, a novel derivative of memantine, facilitates extinction learning without sensorimotor deficits. Int J Neuropsychopharmacol. 2021 Feb 25;pyab007. [3]. Chen BK, et, al. Fluoroethylnormemantine, a novel NMDA receptor antagonist, for the prevention and treatment of stress-induced maladaptive behavior. Biological Psychiatry. 2021 May 9.